Skip to main content
Top
Published in: Acta Diabetologica 3/2024

Open Access 06-11-2023 | Diabetes | Original Article

Scans per day as predictors of optimal glycemic control in people with type 1 diabetes mellitus using flash glucose monitoring: what number of scans per day should raise a red flag?

Authors: Fernando Sebastian-Valles, Julia Martínez-Alfonso, Jose Alfonso Arranz Martin, Jessica Jiménez-Díaz, Iñigo Hernando Alday, Victor Navas-Moreno, Teresa Armenta Joya, Maria del Mar Fandiño García, Gisela Liz Román Gómez, Luis Eduardo Lander Lobariñas, Purificación Martinez de Icaya, Miguel Antonio Sampedro-Nuñez, Vicente Martínez-Vizacaíno, Mónica Marazuela

Published in: Acta Diabetologica | Issue 3/2024

Login to get access

Abstract

Aims

This study aimed to determine the minimum frequency of flash glucose monitoring (FGM) scans necessary for optimal glycemic control in patients with type 1 diabetes (T1D).

Methods

Data were collected from 692 patients (47.5% female, with a median age of 47.4 years) who used FGM systems daily and recorded their clinical variables and device data.

Results

Logistic regression models showed that performing more than 12 scans per day was associated with improved T1D control (OR = 4.22, p < 0.001) and a reduction in HbA1c (7.6 vs 7.0%, 60–53 mmol/mol p < 0.001). However, those performing less than 6 scans showed no improvement in HbA1c (7.9 vs 7.8%, 63–61 mmol/mol p = 0.514). Thirteen daily scans were determined as the optimal cutoff point for predicting optimal glycemic control using a maximally selected rank algorithm. Significant reductions were observed in mean glucose (< 0.001), coefficient of variation (< 0.001), HbA1c (< 0.001), and an increase in TIR (< 0.001) in patients who performed more than 12 daily scans.

Conclusions

The results suggest that a higher frequency of daily scans by T1D patients using FGM systems leads to improved chronic glycemic control. The minimum recommended frequency for optimal control is 13 scans per day, and more than 6 daily scans are needed to improve HbA1c.
Appendix
Available only for authorised users
Literature
18.
go back to reference Team R Core R: A language and environment for statistical computing. Published online 2013 Team R Core R: A language and environment for statistical computing. Published online 2013
19.
go back to reference Hothorn T, Hothorn MT, Suggests TH. Package ‘maxstat.’ Published online 2017 Hothorn T, Hothorn MT, Suggests TH. Package ‘maxstat.’ Published online 2017
32.
Metadata
Title
Scans per day as predictors of optimal glycemic control in people with type 1 diabetes mellitus using flash glucose monitoring: what number of scans per day should raise a red flag?
Authors
Fernando Sebastian-Valles
Julia Martínez-Alfonso
Jose Alfonso Arranz Martin
Jessica Jiménez-Díaz
Iñigo Hernando Alday
Victor Navas-Moreno
Teresa Armenta Joya
Maria del Mar Fandiño García
Gisela Liz Román Gómez
Luis Eduardo Lander Lobariñas
Purificación Martinez de Icaya
Miguel Antonio Sampedro-Nuñez
Vicente Martínez-Vizacaíno
Mónica Marazuela
Publication date
06-11-2023
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2024
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-023-02204-x

Other articles of this Issue 3/2024

Acta Diabetologica 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine